Pharmacodynamic studies examine the relationship between drug pharmacokinetics and outcome. These investigations have been shown to be helpful for the design of dosing intervals, choice of optimal dose levels, and the development of susceptibility breakpoints. Pharmacodynamic studies with available antifungal agents have been useful in developing optimal dosing regimens to improve efficacy and reduce treatment-associated toxicities. This review summarizes accepted antifungal concepts and discusses recent advances in the field.
Introduction
Pharmacokinetic (PK) studies examine how the body handles drugs, including absorption, distribution, metabolism, and elimination. Pharmacodynamic (PD) studies examine the integration of a drug's PK properties and outcome. The past decade has seen numerous investigations, both in vitro and in vivo, examining the PK and PD properties of antifungal agents. Each of the available classes of systemic antifungal therapy have been examined with regards to the PD indice predictive of optimal efficacy. Knowledge of the PK/PD indice and magnitude associated with efficacy is vital for clinicians to predict therapeutic success/failure, guide optimal dosing levels and intervals, aid in susceptibility breakpoint development, guide therapeutic drug monitoring, and limit potential adverse outcomes, including toxicity and the development of resistance [1] . The following discusses the PD properties of systemic antifungal therapy, with an emphasis on new developments, including clinical PD validation, tissue PK considerations, therapeutic drug monitoring, and emergence of resistance. [2] . Most recently, these questions have been investigated for the drugs from the new echinocandin class [3,4•,5,6,7•,8] . In addition, studies have also initiated examination of these relationships in Aspergillus species infection models [9] . Other studies have begun to incorporate comparison of serum and tissue PK into the PD analyses [10,11•,12,13] . Most recently, experiments have been designed to investigate the correlation between antifungal PD and the emergence of drug-resistant fungal populations [14•,15•,16] . Additional studies in these newer PD areas are needed. However, understanding these relationships for combination antifungal therapy remains the area of greatest need in the field of antifungal PD.
Pharmacodynamic Indice Determination
Antimicrobial PD examines the relationship between drug PK, a measure of in vitro potency (usually the minimum inhibitory concentration [MIC] ), and the treatment outcome (usually efficacy or sometimes drug toxicity) [1] . Three PD indices have been used to describe these relationships, including peak concentrations in relation to the MIC (Cmax/MIC), the area under the concentration curve in relation to the MIC (AUC/MIC), and the time (expressed as a percentage of the dosing interval) that the drug concentrations exceed the MIC (%T>MIC) (Fig. 1) . Determining which of the three PD indices is predictive of efficacy provides a framework for dosing regimen design. For example, dosing of concentration-dependent killing antimicrobials is optimal when large doses are administered infrequently. The concentration-dependent indices, Cmax/MIC and AUC/MIC, are the PD indices associated with treatment effect for these compounds. Conversely, efficacy with drugs that exhibit optimal efficacy at concentrations near the MIC or time-dependent killing antimicrobials is greatest when smaller doses are given frequently. This regimen will keep drug concentrations above the organism's MIC, and therefore, the predictive indice is the %T>MIC.
Two experimental approaches have been used to examine the PD properties of an antimicrobial agent. The first design examines the impact of escalating drug concentrations on the extent and rate of organism killing or growth inhibition over time. The second outcome considered in these investigations is the antimicrobial effect after either the drug has been removed (in vitro models) or after concentrations have fallen below the MIC (in vivo models). The phenomenon of growth suppression following antifungal exposure is called the postantifungal effect (PAFE). For some compounds, organism growth suppression persists for prolonged periods of time after drug exposure, allowing for lengthening of the dosing interval. The PAFE is usually concentration-dependent; the duration usually increases with higher concentrations or doses. Thus, the activity of drugs exhibiting prolonged PAFEs is best described by the Cmax/MIC or AUC/MIC indices.
The second study approach critical for determining PD relationships is dose fractionation. Practically, this is carried out by administering a wide range of total dose levels and changing the interval of administration. This experimental design reduces the interdependence among the three PD indices. The highest, most infrequently administered dose will have the highest administered peak concentrations, whereas the lowest dose most frequently will have the highest %T>MIC. The AUC (total drug exposure) of any total dose often remains similar in dose fractionation. Using this scheme, one can investigate which dosing interval results in optimal efficacy. If regimens using higher, infrequent dosing result in lower fungal burdens, then the PD indice predictive of efficacy is related to peak concentrations (Cmax). If regimens using frequent, small doses result in lower fungal burdens, then the PD indice predictive of efficacy is the %T>MIC. If efficacy is similar in each of the dosing intervals, then outcome depends on total drug exposure (AUC/MIC). These relationships are further analyzed by expressing each dosing regimen as the Cmax/MIC, AUC/MIC, and %T>MIC and then modeling the relationship between each PD indice and treatment effect.
Pharmacodynamic Indice Target Determination and Clinical Validation
With knowledge the predictive PD indice, one can begin to design antifungal dosing regimens from the standpoint of the dosing interval. The next important and logical question is how much drug is needed to achieve the outcome of interest or what is the PD target. The experimental approach to these questions involves examining the impact of a wide range of antimicrobial exposures against a large number of organisms with varying MICs. A variety of treatment endpoints can be considered, often including the PD magnitude needed to produce 1) 50% of the maximal effect, 2) a net static effect or keeping the organism burden the same as at the start of therapy, or 3) a range of quantitative reductions in organism burden, such as 1 or 2 log kill.
The final and most important PD question involves determining if the results from the preceding preclinical investigations are helpful for predicting efficacy in patients. The analysis needed for this correlation requires clinical data sets that include drug dose or drug concentration monitoring, organism MIC, and treatment efficacy. These data can be used to determine the PD exposure associated with an acceptable outcome and to determine which treatment endpoint from preclinical models (eg, 50% maximal effect) correlates with efficacy in patients.
Antifungal Class-based Pharmacodynamics

Polyenes
Most PD investigation has been undertaken with conventional amphotericin B deoxycholate. In vitro and in vivo Candida species infection models have examined the PD characteristics of this antifungal compound [17-20,21•] . Results from both model types have been congruent and have observed killing of Candida species that increases as the concentration of amphotericin B is escalated multiple times above the MIC. These Candida infection models have also shown that growth inhibition following amphotericin B exposure continues for long periods of time (long PAFEs) [18, 19, 22] . In vivo dose fractionation studies in a Candida model demonstrated optimal efficacy when large doses were administered infrequently, and PD analysis of the dose fractionation data illustrates that the Cmax/MIC indice best predicts efficacy [17, 18] . With each increase in length of the dosing interval from every 12 to 72 hours, efficacy was enhanced and the dose needed to achieve a net static effect was up to 10-fold lower when administered with the most widely spaced dosing interval. Study with multiple Candida organisms suggests that the PD target needed to achieve a stasis endpoint is achieved with Cmax/MIC values near 2 and significant organism reductions (1 log) were observed for Cmax/MIC exposures near 4. More recently, a similar experimental approach was undertaken in an in vivo Aspergillus model. Over a fourfold total dose range, the lung burden of Aspergillus was significantly lower when amphotericin B was administered every 72 hours compared with every 8 or 24 hours [21•] . These data also suggest that the Cmax/MIC indice is predictive of efficacy. In the same Aspergillus pneumonia model, maximal animal survival was observed when the amphotericin B-Cmax/MIC ratio approaches 2. These important results demonstrate that the PD relationships for amphotericin B are comparable for both Candida and Aspergillus species. Unfortunately, amphotericin B clinical data sets that provide the necessary PK, MIC, and outcome information for PD analysis do not exist [23] . [11•,12,17] . Not surprisingly, both in vitro and in vivo studies with these lipid formulations have also demonstrated concentration-dependent activity. One previously recognized difference between conventional and each of the lipid formulations of amphotericin B is a difference in potency on a mg/kg basis. Recent PD investigation confirmed and quantified this difference in potency. In a murine model of invasive candidiasis, both ABLC and LAmB were 4.3-to 5.9-fold less potent than amphotericin B deoxycholate on a mg/kg basis [17] .
PD analyses have also been recently undertaken with the three lipid formulations of amphotericin B (liposomal amphotericin B [LAmB], amphotericin B lipid complex [ABLC], and amphotericin B colloidal dispersion [ABCD])
PK studies with these amphotericin B compounds have also demonstrated differences in serum and tissue PK [10,11•,12] . For most tissue sites, serum concentrations are excellent predictors of interstitial tissue concentrations where most fungal pathogens reside during infection. However, there are certain tissue sites for which there can be discrepancies, including the central nervous system (CNS), eye, and a compartment of the lung called the epithelial lining fluid. The lipid formulations have variable tissue kinetics and penetration that are largely dependent on their carrier molecule. For example, LAmB is a small, unilamellar particle that exhibits high serum and CNS concentrations (likely due to a large serum-CNS gradient) relative to the other amphotericin B preparations [10] . Conversely, ABLC and ABCD achieve higher concentrations in the intracellular space and in organs of the reticuloendothelial system [24] . Several studies have also suggested that ABLC attains higher concentrations in the lung than other formulations [11•,12] . Recent investigations have explored the impact of these PK differences on PD outcomes. For example, study in an in vivo candidiasis model demonstrated that the difference in potency among the lipid preparations in the lungs, kidneys, and liver were congruent with tissue kinetics in these organs [17] . A novel study in a CNS candidiasis model examined the relationship between kinetics in serum, cerebrospinal fluid, and brain parenchyma [10] . The kinetic studies demonstrated no significant difference in cerebrospinal fluid concentrations but higher brain concentrations of LAmB. The brain parenchymal differences in kinetics correlated closely with treatment efficacy in the model for which LAmB appeared to have an advantage. Similar investigations in Aspergillus pneumonia models have included assessment of lung tissue concentrations [11•,12] . These studies also suggested a relationship between these lung tissue site concentrations and efficacy. In this case, ABLC appears to be favored. Recent studies have also begun to consider compartmental PK in the lung. Specifically, study in a murine model examined total lung, epithelial lining fluid, and pulmonary macrophage concentrations of each of the amphotericin B preparations [11•] . As in previous studies, ABLC produced higher lung concentrations (70-fold higher than serum concentrations); however, a large amount of the compound appeared to reside in pulmonary alveolar macrophages. The highest epithelial lining fluid concentrations were noted in LAmBtreated animals. Determination of the impact of these PK differences has not yet been reported.
Flucytosine
PD study of flucytosine (5-FC) has also been undertaken with both in vitro and in vivo candidiasis models [22,25,26•,27,28] . These investigations have identified a PD pattern of activity distinct from that seen with the polyenes. The antifungal activity of 5-FC is maximal at concentrations not far above the MIC. Exposure to higher concentrations does not impact the extent of organism killing (time-dependent killing). Dosing regimen design for a drug with this pattern of activity would be optimized by prolonging concentrations above the MIC. Dose fractionation studies corroborate the influence of this dosing strategy. Small, frequently administered 5-FC was most efficacious in the in vivo disseminated candidiasis model. In fact, the total amount of drug needed to achieve a net static effect was up to 15-fold less following administration of small doses every 3 hours than by giving larger amounts every 6, 12, or 24 hours [25, 27] . PD indice analysis of this data set further demonstrates that the %T>MIC was associated with efficacy. The indice magnitude for which optimal efficacy was noted in this model was a time above MIC magnitude of only 40% of the dosing interval. Although 5-FC is used primarily for Candida and Cryptococcus species infections, a recent PD investigation in an in vivo aspergillosis model similarly examined the impact of dose fractionation. As with multiple fungal species investigation with amphotericin B, these experiments with 5-FC demonstrate that PD relationships are similar among fungal species. The most fractionated 5-FC regimen (every 6 h) was more efficacious than the more widely spaced dosing interval regimens (every 12 and 24 h) [28] . Unfortunately, there has not been PD study with the most clinically relevant organism and infection site, Cryptococcus neoformans and meningitis. Study in this model may offer critical dosing regimen strategies for this compound with a relatively narrow therapeutic index. In addition, there are no clinical data sets that allow PD analysis with 5-FC. However, one group of investigators have provided a model of human 5-FC PK relative to the %T>MIC target again Candida species in a murine model [26•] . Similar to previous reports, the %T>MIC magnitude associated with efficacy in this model was a value near 40% to 50%. The group then considered the PK of a range of 5-FC doses and the MIC distribution for Candida albicans. Interestingly, doses as low as 25 mg/kg/d (sixfold lower than the currently recommended regimen) would be predicted to achieve the PD target against organisms in the current MIC distribution. Again, the major gap in PD knowledge for 5-FC remains characterization in a cryptococcal meningitis model to determine if these relationships and the PD target are similar. Because the primary toxicity of 5-FC is associated with high peak concentrations, this PD information has the potential to provide an efficacious, yet much less toxic dosing strategy.
Triazoles
Extensive PD investigation has been undertaken with drugs from the triazole antifungal drug class. Data with each of these compounds have produced equivalent results demonstrating that PD relationships are similar within a drug class [19, 20, [29] [30] [31] [32] [33] [34] . Essentially, all of these studies have used Candida species models. The observations have shown that triazoles exhibit growth inhibition at concentrations near the MIC much like that observed with 5-FC (concentration-independent activity). However, in vivo experiments demonstrated prolonged periods of growth suppression (PAFEs) after triazole concentrations fall below the MIC [29] [30] [31] [32] . The duration of PAFE was shown to increase with dose escalation (concentration-dependent PAFE). In vivo dose fractionation studies for each of the triazoles examined have found that efficacy is dependent upon the dose of drug but similar among the various dosing intervals [29] [30] [31] [32] [33] [34] . The 24-hour AUC/MIC indice correlates most strongly with efficacy in PD analysis of the fractionation data. In vivo studies against a large number of Candida species with widely varying MICs (more than 2000-fold) have demonstrated that the 24-hour AUC/MIC associated with efficacy (50% maximal effect) for triazoles occurs at a value near 25 [29] [30] [31] [32] . This value can be simplistically thought of as averaging concentrations at the MIC over a 24-hour period (1 x MIC x 24 hours). These in vivo disseminated candidiasis studies have also demonstrated that PD relationships are similar for drugs with a similar mechanism of action as long as free (non-protein bound) drug concentrations are considered. An important unanswered question is whether these relationships and PD indice values for triazoles are similar for filamentous fungal species, such as Aspergillus.
For fluconazole, numerous large clinical studies have provided sufficient data (drug dose, MIC, and outcome) for PD analysis [35•,36,37,38•,39,40•,41] . The earliest and largest of these data sets (> 1000 patients) emanated from studies in oropharyngeal candidiasis [39] . Analysis demonstrated that treatment efficacy was maximal with fluconazole exposures relative to the MIC of the infecting Candida species near a 24-hour AUC/MIC value of 25, congruent with data from the in vivo models. In the largest single analysis, when the fluconazole dose/MIC (AUC/MIC) exceeded 25, clinical success was noted in 91% to 100% of patients [39] There is now detailed fluconazole PD information for more than 600 episodes of candidemia. These data have identified a remarkably similar triazole exposure-clinical response relationship, with both clinical efficacy and patient survival associated with a fluconazole 24-hour AUC/MIC ranging from 25 to 50. For example, in a study of nearly 90 episodes of candidemia with classification and regression tree analysis of dose and MIC, the critical AUC/MIC value associated with patient survival (80% vs 50%) was 25 [35•] . A similar clinical analysis is now also available for voriconazole [42] . The dataset includes 1681 isolates of 16 different Candida species from more than 400 patients during six phase 3 clinical trials. Analysis demonstrated a strong relationship between MIC and outcome. If one estimates the free drug AUC for the voriconazole regimen used in these trials, AUC/ MIC can then be calculated using the geometric mean MIC for each of the species. Based on this analysis, therapeutic success was observed in 72% to 85% of patients with 24-hour AUC/MIC greater than 25, whereas when AUC/MIC was less than 25, clinical failure was noted in 45% of patients. Unfortunately, to date, there is not a complete data set for aspergillosis that allows similar analysis. However, there have been several recent voriconazole therapeutic drug monitoring publications that do allow PD estimation [43•,44•] . Two studies observed clinical success and patient survival, respectively, with voriconazole serum trough concentrations ranging from 1 to 2 g/mL for patients with invasive aspergillosis. If one considers the free drug AUC associated with these trough concentrations and the MIC90 for voriconazole and Aspergillus, the resulting 24-hour AUC/MIC value is near 25. Thus, one can use this drug-monitoring information to examine efficacy from the PD standpoint. It will be critical to include therapeutic drug monitoring in future studies with these compounds and to include MIC testing when an organism is available. A similar concentration/outcome relationship has also been recently reported for posaconazole in patients with invasive aspergillosis. In 67 patients with invasive aspergillosis and serum concentration monitoring, the posaconazole average concentration at steady state ranged from 0.13 to 1.25 g/mL [45•] . Maximal clinical response (75%) was observed in the cohort with the highest posaconazole concentration (1.25 g/mL), whereas the least successful group (24% success) was found to have the lowest posaconazole serum levels.
Most PD investigations have targeted the identification of dosing strategies to optimize efficacy. More recently, a number of groups have begun to use PD analysis to understand the relationship between antimicrobial use and resistance development [14•,15•,16] . The goal of these studies is to identify dosing approaches that lead or delay the emergence of resistance to further optimize outcomes in patients and extend the useful lifespan of available antifungals. The first experiments in these studies attempted to determine if different PD exposures were associated with the emergence of resistant fungi. Initial studies focused on the best pharmacodynamically characterized antifungal drug-fungal combination, fluconazole and C. albicans. The PD design was similar to that used in dose fractionation studies. Two in vivo experimental models were used; both tracked populations who were susceptible and resistant to fluconazole over time. Both experimental models observed the emergence of a resistance population that increased in burden over time. Interestingly, the dosing regimen relationship observed for fluconazole treatment efficacy was distinct from that for resistance emergence. For efficacy, outcome was dependent on the dose of drug and independent of the dosing interval. However, the most fractionated (shortest dosing interval) fluconazole regimens reduced or prevented the emergence of resistance. Conversely, the growth of large numbers of fluconazole resistance C. albicans was seen with the most widely spaced intervals. PD analysis of these data demonstrated that the %T>MIC was the indice which best described the resistance emergence relationship (24-h AUC/MIC for treatment efficacy). Further investigation of this relationship suggested that prolonged concentrations below the fluconazole MIC (or sub-MIC exposures) led to resistance. The Candida cell populations collected during these investigations were also examined transcriptionally using both microarrays and real-time polymerase chain reaction to examine the relationship between PD and expression of known resistance genes. In addition, these data were used to further understand the resistance development process from a mechanistic standpoint. Interestingly, the PD relationships observed for the microbiologic endpoints (growth of resistant Candida) mirrored the expression profile of known resistance genes (both efflux pumps [CDR1 and CDR2] and the ergosterol synthesis drug target [ERG11]). It will be interesting to determine if these relationships are similar for other antifungal drug classes and other fungal species. Further studies examining the relationships of antifungal dosing regimens, PD indices, and emergence of resistance will be vital to continued efficacy of the currently available antifungals.
Echinocandins
Numerous in vitro and in vivo studies with compounds from the echinocandin drug class have been undertaken using Candida models [3,4•,5,6,7•,8,19] . Results from these investigations have been consistent. Each of the compounds has exhibited pronounced concentration-dependent killing effects and prolonged PAFEs [3,4•,5,8,19] . In vivo dose fractionation studies with several echinocandins in models of C. albicans and Candida glabrata demonstrated that administration of large doses infrequently was optimal for efficacy [3,4•] . For example, a study with aminocandin demonstrated that giving high doses infrequently led to a fourfold reduction in the total dose necessary for efficacy when compared with the most fractionated regimen [3] . Analysis of these data confirmed the importance of the concentration-associated indices, Cmax/MIC and AUC/MIC. Initial PD studies with these compounds used serum PD. More recent studies have also examined the impact of tissue concentrations at the site of infection [7•]. Dose-response relationships were similar in these investigations and support a dosing strategy that involves administration of large doses given infrequently. A recent clinical study with micafungin explored this dosing strategy in an esophageal candidiasis trial [46• ]. The two micafungin dosing regimens examined included the standard regimen of 150 mg daily in comparison to a regimen of 300 mg every other day. The total drug exposure or AUC would be similar for the two regimens. Interestingly, clinical and microbiologic efficacy were similar for both regimens, consistent with results from the preclinical models. It will be interesting to see if additional lengthening of the dosing interval can be explored in clinical trials. In animal models, the dosing interval has been successfully lengthened to every 7 days while maintaining efficacy [47•] . A similar approach has also been undertaken with caspofungin in an in vivo model of aspergillosis [9•] . In these dose fractionation studies, outcome was optimal with regimens that maximized drug exposure. Studies in this aspergillosis model further support the contention that antifungal PD relationships for a drug class are similar among fungal organisms.
Recent studies have also begun to explore the magnitude of the Cmax/MIC and AUC/MIC indices needed for treatment efficacy [4•]. Experimentation with anidulafungin against 15 C. albicans and C. glabrata isolates demonstrated similar exposure response relationships for both species when expressed as either the 24-hour AUC/MIC or Cmax/MIC indices. The PD target associated with achievement of a stasis endpoint corresponded to an anidulafungin free drug (non-protein bound) 24-hour AUC/MIC from 10 to 20. The Cmax/MIC needed to produce this degree of treatment success was a value near 1. Recent data with micafungin with this same group of organisms were very similar (Andes, unpublished data). If one considers these PD targets in the context of human PK of these compounds and the MIC distribution for these two Candida species, one would predict treatment success (AUC/MIC > 10 and Cmax/MIC > 1). However, the kinetics of these compounds would not achieve this target against Candida parapsilosis species for which the MICs are nearly an order of magnitude higher [48] . It remains to be seen whether the PD target is similar for this species. Certainly, clinical trial results with these compounds have demonstrated treatment success against these organisms despite higher MICs. It is possible or even likely that the PD target or hurdle with this less virulent species may be lower than for C. albicans or C. glabrata. The echinocandin PD target in therapy of Aspergillus infections has not been as extensively examined. However, in study against a single isolate, the caspofungin, Cmax/ MIC value associated with maximal efficacy in a murine model was near 1 to 2 [9•] .
Another area of intense interest for the echinocandin class against Aspergillus infections is combination therapy with mold-active triazoles. Numerous in vitro and in vivo studies have examined the impact of this combination [49] [50] [51] [52] [53] . The interpretation of the efficacy data from these investigations have varied from suggesting an enhanced interaction to antagonism. Drug exposure from a dose level standpoint has been considered in several of these studies. However, extensive PK/PD design and analysis remain, for the most part, unexplored in the area of antifungal combination. The analyses from a few studies suggest the importance of this additional level of investigation. For example, in study of the combination of the echinocandin, caspofungin, and the triazole, voriconazole, the impact of the interaction was dependent upon the dose of the echinocandin [53] . Among the unanswered antifungal PD questions, detailed examination of combination therapy is among the most important.
Conclusions
PD studies have been pivotal in the development of optimal dosing regimens for available antifungals with the focus of optimizing efficacy and reducing potential toxicities. Using PD studies, one can determine which PK indice and indice magnitude is associated with optimal efficacy. These data have been helpful for dosing regimen design and for development of susceptibility breakpoints. Studies with drugs from each of the available antifungal drug classes have demonstrated the utility of these studies in the treatment of Candida infections. More recently, studies have begun to demonstrate the relevance of these approaches for optimizing therapy against filamentous fungi. Yet, many important questions remain unanswered. Current investigations are beginning to explore some of these issues including the impact of PD on resistance development, therapeutic drug monitoring, tissue kinetics and efficacy and in understanding the impact of combination therapy.
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